# Precision BioSciences Shares Phase 1 ELIMINATE-B Data

> Precision BioSciences presents Phase 1 ELIMINATE-B results for PBGENE-HBV in chronic hepatitis B.
- Title: Precision BioSciences Shares Phase 1 ELIMINATE-B Data
- Summary: Precision BioSciences presents Phase 1 ELIMINATE-B results for PBGENE-HBV in chronic hepatitis B.
- Keywords: precision biosciences, pbgene-hbv, chronic hepatitis b, phase 1, aasld 2026, investor update, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4965111-precision-biosciences-inc-dtil-discusses-phase-1-eliminate-b-data-for-pbgene-hbv-in-chronic
- Published: 2026-11-09T22:10:54+00:00
- Read time: 1 min
- Topics: precision biosciences, pbgene-hbv, chronic hepatitis b, phase 1, aasld 2026, investor update, money, business
## Company Shares Phase 1 ELIMINATE-B Data
Precision BioSciences presented Phase 1 ELIMINATE-B data for PBGENE-HBV in chronic hepatitis B at AASLD 2026.
## Key Executives Attend Investor Update
Naresh Tanna, CFO; Michael Amoroso, CEO; and Cassie Gorsuch, Chief Scientific Officer joined the call.
## Hepatology Experts Join Presentation
Dr. Mark Sulkowski from Johns Hopkins Bayview and Dr. MF Yuen from University of Hong Kong provided expert insights.
## Key takeaway

Precision BioSciences shared Phase 1 ELIMINATE-B data for PBGENE-HBV in chronic hepatitis B at AASLD 2026.